ArticleSignal transduction and targeted therapy2023
Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus.
Article in Signal transduction and targeted therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 104 citations in OpenAlex.
- An integrated review of monkeypox: from pathogen and epidemiology to diagnostics, control, and challenges.Emerging microbes & infections · 2026Review
- mRNA lipid nanoparticle vaccines: current status, challenges and future prospects.Molecular biomedicine · 2026Review
- A single-dose inhalable rAAV-vectored vaccine against mpox virus.Cell reports. Medicine · 2026Article
- Current Strategies for Selecting Recombinant Orthopoxvirus Proteins for Immunobiological and Diagnostic Applications.Viruses · 2026Review
- MPXV H3L elicits broadly directed CD4 T cell responses in mpox patients and MVA vaccinees.Npj viruses · 2026Article
- Inhalable engineered probiotic outer membrane vesicles co-expressing multiple mpox antigens induce potent specific systemic and mucosal immune responses.Materials today. Bio · 2026Article
- Circular RNA vaccines encoding fusion proteins of Mpox Virus A35R-M1R and B6R-A29L induce robust and durable protective immunity in mice.Journal of nanobiotechnology · 2026Article
- mRNA vaccines against monkeypox: bridging immunoinformatics, structural vaccinology, and translational advances toward pan-orthopox immunity.Folia microbiologica · 2026Review
- Article
- Article
- Therapeutic mRNA vaccines for lung cancer: reshaping the tumor microenvironment to enhance anti-tumor immunity.Frontiers in immunology · 2026Review
- Monkeypox Virus Countermeasures: Vaccines, Antibodies, Drugs and Traditional Chinese Medicine.Drug design, development and therapy · 2026Review
- Comparative humoral profiles in mpox cases, survivors, and vaccinated individuals reveal correlates of protection against MPXV.Cell reports. Medicine · 2025Article
- Nanotechnology in COVID-19 prevention, diagnosis, and treatment: a comprehensive review.Discover nano · 2025Review
- mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics.Cancer innovation · 2025Review
- A bivalent Mpox nanoparticle vaccine induces robust immune response and provides long-lasting protection against vaccinia virus challenge.Emerging microbes & infections · 2025Article
- Rational mpox vaccine design: immunogenicity and protective effect of individual and multicomponent proteins in mice.Emerging microbes & infections · 2025Article
- Lyophilized monkeypox mRNA lipid nanoparticle vaccines with long-term stability and robust immune responses in mice.Human vaccines & immunotherapeutics · 2025Article
- mRNA vaccines: immunogenicity and quality characteristics.Journal of nanobiotechnology · 2025Review
- Emerging strategies for monkeypox: antigen and antibody applications in diagnostics, vaccines, and treatments.Military Medical Research · 2025Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monkeypox has been declared a public health emergency by the World Health Organization. There is an urgent need for efficient and safe vaccines against the monkeypox virus (MPXV) in response to the rapidly spreading monkeypox epidemic. In the age of COVID-19, mRNA vaccines have been highly successful and emerged as platforms enabling rapid development and large-scale preparation. Here, we develop two MPXV quadrivalent mRNA vaccines, named mRNA-A-LNP and mRNA-B-LNP, based on two intracellular mature virus specific proteins (A29L and M1R) and two extracellular enveloped virus specific proteins (A35R and B6R). By administering mRNA-A-LNP and mRNA-B-LNP intramuscularly twice, mice induce MPXV specific IgG antibodies and potent vaccinia virus (VACV) specific neutralizing antibodies. Further, it elicits efficient MPXV specific Th-1 biased cellular immunity, as well as durable effector memory T and germinal center B cell responses in mice. In addition, two doses of mRNA-A-LNP and mRNA-B-LNP are protective against the VACV challenge in mice. And, the passive transfer of sera from mRNA-A-LNP and mRNA-B-LNP-immunized mice protects nude mice against the VACV challenge. Overall, our results demonstrate that mRNA-A-LNP and mRNA-B-LNP appear to be safe and effective vaccine candidates against monkeypox epidemics, as well as against outbreaks caused by other orthopoxviruses, including the smallpox virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.